Empirical treatment of urinary tract infections: how rational are our guidelines?
- 8 October 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 74 (1), 214-217
- https://doi.org/10.1093/jac/dky405
Abstract
Objectives: This study considers susceptibility test results obtained over a 6 month period for Enterobacteriaceae that caused urinary tract infections (UTIs) in the Cork region of Ireland and uses these results to examine the suitability of Irish empirical treatment guidelines. Patients and methods: UTI-causing Enterobacteriaceae isolates were analysed using EUCAST guidelines to determine resistance to a set of commonly prescribed antimicrobial agents, i.e. ampicillin, amoxicillin/clavulanate, cefalexin, ciprofloxacin, nitrofurantoin and trimethoprim. Patients were categorized by age and patient type, based on origin (hospital inpatients, patients in long-term care facilities and all other non-hospitalized patients). In total, 8999 test results were analysed using the IBM Cognos Analytics Series 7 interrogation tool and Microsoft Office Excel. Results: A variety of resistance patterns were observed. Only one antimicrobial agent, nitrofurantoin, demonstrated a resistance rate of less than 20% for all patient categories considered. Conclusions: Previous studies determined that a resistance rate of >20% renders an antimicrobial agent unsuitable for use as an empirical treatment option. This study demonstrated that this resistance rate is exceeded in many cases, potentially rendering some antimicrobial agents unsuitable for use as empirical treatment. We suggest that the focus on susceptibility when producing surveillance data to create empirical treatment guidelines may inadvertently camouflage resistance rates. The findings of this study highlight the need for laboratory-guided treatment of UTIs and ideally a pre-emptive sample should be obtained for laboratory investigation prior to commencement of antimicrobial therapy.Keywords
This publication has 11 references indexed in Scilit:
- Trimethoprim use for urinary tract infection and risk of adverse outcomes in older patients: cohort studyBMJ, 2018
- Trends in Antibiotic Resistance in Urologic PracticeEuropean Urology Focus, 2016
- Urinary Tract Infections due to Multidrug-Resistant Enterobacteriaceae: Prevalence and Risk Factors in a Chicago Emergency DepartmentEmergency Medicine International, 2013
- Different recommendations for empiric first-choice antibiotic treatment of uncomplicated urinary tract infections in EuropeScandinavian Journal of Primary Health Care, 2013
- Benchmarking inappropriate empirical antibiotic treatmentClinical Microbiology & Infection, 2013
- Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO·SENS study revisitedInternational Journal of Antimicrobial Agents, 2011
- International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious DiseasesClinical Infectious Diseases, 2011
- The epidemiology of urinary tract infectionNature Reviews Urology, 2010
- Antibiotic use and population ecology: How you can reduce your "resistance footprint"CMAJ : Canadian Medical Association Journal, 2009
- Empiric Use of Trimethoprim‐Sulfamethoxazole (TMP‐SMX) in the Treatment of Women with Uncomplicated Urinary Tract Infections, in a Geographical Area with a High Prevalence of TMP‐SMX–Resistant UropathogensClinical Infectious Diseases, 2002